Persistence of neutralizing antibody 30-35 years after immunization with 17D yellow fever vaccine
about
Vaccines: from empirical development to rational designThe global distribution of the arbovirus vectors Aedes aegypti and Ae. albopictusThe 17D-204 Vaccine Strain-Induced Protection against Virulent Yellow Fever Virus Is Mediated by Humoral Immunity and CD4+ but not CD8+ T CellsGuiding dengue vaccine development using knowledge gained from the success of the yellow fever vaccineThe yellow fever 17D virus as a platform for new live attenuated vaccinesVaccine-mediated immunity against dengue and the potential for long-term protection against diseaseBooster dose after 10 years is recommended following 17DD-YF primary vaccinationRecombinant yellow fever viruses are effective therapeutic vaccines for treatment of murine experimental solid tumors and pulmonary metastases.Chimeric yellow fever/dengue virus as a candidate dengue vaccine: quantitation of the dengue virus-specific CD8 T-cell responseA live, attenuated recombinant West Nile virus vaccine.Activation/modulation of adaptive immunity emerges simultaneously after 17DD yellow fever first-time vaccination: is this the key to prevent severe adverse reactions following immunization?Live attenuated yellow fever 17D infects human DCs and allows for presentation of endogenous and recombinant T cell epitopesThe effect of immune globulin on the response to trivalent oral poliovirus and yellow fever vaccinationsYellow fever vaccine induces integrated multilineage and polyfunctional immune responsesComprehensive analysis of T cell epitope discovery strategies using 17DD yellow fever virus structural proteins and BALB/c (H2d) mice modelYellow Fever in Pará State, Amazon Region of Brazil, 1998-1999: Entomologic and Epidemiologic FindingsAdvanced Age a Risk Factor for Illness Temporally Associated with Yellow Fever VaccinationDynamics of the CD8 T-cell response following yellow fever virus 17D immunizationImmune activation alters cellular and humoral responses to yellow fever 17D vaccineT-cell memory responses elicited by yellow fever vaccine are targeted to overlapping epitopes containing multiple HLA-I and -II binding motifsYellow Fever in Africa: estimating the burden of disease and impact of mass vaccination from outbreak and serological dataMeasurements of immune responses for establishing correlates of vaccine protection against HIVPrevalence and titers of yellow fever virus neutralizing antibodies in previously vaccinated adultsAdaptive immune responses to booster vaccination against yellow fever virus are much reduced compared to those after primary vaccinationT Cell-Mediated Immunity towards Yellow Fever Virus and Useful Animal ModelsCD4+ and CD8+ T-cell immunity to Dengue - lessons for the study of Zika virus.Flaviviruses, an expanding threat in public health: focus on dengue, West Nile, and Japanese encephalitis virus.Assessment of yellow fever epidemic risk: an original multi-criteria modeling approach.T-bet+ B cells are induced by human viral infections and dominate the HIV gp140 response.Meta-analysis of all immune epitope data in the Flavivirus genus: inventory of current immune epitope data status in the context of virus immunity and immunopathology.How advances in immunology provide insight into improving vaccine efficacy.RNA virus reverse genetics and vaccine design.Yellow fever: a reemerging threatPhase II, randomized, double-blind, placebo-controlled, multicenter study to investigate the immunogenicity and safety of a West Nile virus vaccine in healthy adultsYellow fever vaccine YF-17D activates multiple dendritic cell subsets via TLR2, 7, 8, and 9 to stimulate polyvalent immunity17DD and 17D-213/77 yellow fever substrains trigger a balanced cytokine profile in primary vaccinated children.Transmission dynamics of the four dengue serotypes in southern Vietnam and the potential impact of vaccinationRecombinant yellow fever viruses elicit CD8+ T cell responses and protective immunity against Trypanosoma cruziBiological and immunological characterization of recombinant Yellow Fever 17D viruses expressing a Trypanosoma cruzi Amastigote Surface Protein-2 CD8+ T cell epitope at two distinct regions of the genomeAntibody to dengue 1 detected more than 60 years after infection
P2860
Q21089599-E4ECCDC5-32AA-4E0D-BB23-C078AFA5E714Q22680660-2CC42B02-2EDC-47FB-A2CE-032728A3E496Q26700099-74BC8FE9-3003-4E7C-9FCC-FF1C47613D42Q26782367-C8D3E95B-BF11-43F7-873C-2F2976B62417Q26865102-E30A1F13-10F0-4CAF-8990-E0F9984EFE6EQ27014663-D5AF0DD1-51AD-49CE-A782-75507F2BD2F1Q27468573-AF5CE8F2-38E1-4F42-8162-344C858CAE14Q27469314-DC281F46-1FB5-4789-8D7F-52FF731F7AD8Q27469691-FB0C5B92-5003-4B43-9C50-7709D5F4AEACQ27473138-DBA9E4C2-FB5D-4861-B0B9-937FF9632557Q27478400-A7F58788-06EA-487D-A1C4-9B18B8C1B194Q27485213-AD3A6051-5224-4184-AA34-2860659F1BB8Q27486858-88CF9F0A-06B1-415A-90AF-028E7BFA82FCQ27487514-14282C2E-D9F6-4933-8FB1-201A7E497783Q27487555-F1CE607F-5535-46D1-81B9-1359C385DA4AQ27487826-98DDCEBE-B12B-40EE-AD87-8E37E3C9D2C1Q27487839-24564211-0BC7-4A3E-8AC3-4A8DA02D140EQ27489813-F3D3FCC0-1CC5-4B0C-8BA5-43101724645BQ28388716-46A27F93-0155-4ED0-90E5-B87ECD6D5A73Q28485408-807548A7-51AC-40F3-A09C-1662FF54B11CQ28657892-5A27E306-37D4-4C1F-BEBF-B353A74A929BQ28728189-DF4C0F34-A637-4375-A5DB-6F86C7FFAEF9Q29194011-597EB655-8B32-48BF-A3A8-1297203A1A2CQ29274569-49CEA74F-27DB-40B3-825C-0A35BD401B3CQ29994674-A5DDF87C-A458-401B-8245-7EC8BF9FAFF0Q30394327-1B6CE37D-6906-40F1-AD15-E63F15277969Q30857727-D79393E4-72F6-4CB9-A3E8-3FFAF55682AAQ33481630-BAD9DE98-4EE2-4312-AB6A-D18336C04277Q33578985-779C1769-8635-4254-8879-1DCD4A5DEBEFQ33610555-93D4050B-1EBB-4E8E-BCBF-D6D93AE2E735Q33896995-88D1511A-E160-41C5-ACBD-AE4D7CD1B7EAQ33963398-746D6FDE-7B52-441D-8007-95344F95FA74Q34118209-38FA5967-0D23-415C-AB19-25C2FDBAB6E1Q34154300-C9C6614D-8D79-43F9-A202-58A65ECEAA73Q34491896-48C11BD7-9096-45DF-9B58-8645E3901C0EQ34515690-FC27B8AD-F8A0-43DF-A703-641913B4EC34Q34516283-B7646A3C-7A2B-48E6-BA47-D4ABC04C1D7DQ34635043-80C4257B-F7B3-4A3F-824C-6894F8C28BF2Q34732681-8A7E95CB-7758-4C4A-9F4B-E3F7A71EA9D7Q34883085-FA042FB8-BEFC-4177-A2CD-E9771CC34FB8
P2860
Persistence of neutralizing antibody 30-35 years after immunization with 17D yellow fever vaccine
description
1981 nî lūn-bûn
@nan
1981 թուականին հրատարակուած գիտական յօդուած
@hyw
1981 թվականին հրատարակված գիտական հոդված
@hy
1981年の論文
@ja
1981年論文
@yue
1981年論文
@zh-hant
1981年論文
@zh-hk
1981年論文
@zh-mo
1981年論文
@zh-tw
1981年论文
@wuu
name
Persistence of neutralizing an ...... with 17D yellow fever vaccine
@ast
Persistence of neutralizing an ...... with 17D yellow fever vaccine
@en
Persistence of neutralizing an ...... with 17D yellow fever vaccine
@nl
type
label
Persistence of neutralizing an ...... with 17D yellow fever vaccine
@ast
Persistence of neutralizing an ...... with 17D yellow fever vaccine
@en
Persistence of neutralizing an ...... with 17D yellow fever vaccine
@nl
prefLabel
Persistence of neutralizing an ...... with 17D yellow fever vaccine
@ast
Persistence of neutralizing an ...... with 17D yellow fever vaccine
@en
Persistence of neutralizing an ...... with 17D yellow fever vaccine
@nl
P2093
P2860
P921
P3181
P1476
Persistence of neutralizing an ...... with 17D yellow fever vaccine
@en
P2093
P2860
P304
P3181
P407
P577
1981-01-01T00:00:00Z